UMN-0502 is seasonal influenza vaccine manufactured in insect cells through the use of recombinant DNA technology. Protein Sciences Corporation is developing a novel seasonal influenza candidate in the United States called FluBlok. FluBlok has successfully completed Phase III clinical trials and is awaiting formal marketing approval from the Food and Drug Administration.　UMN Pharma has completed a successful meeting with PMDA regarding future clinical trials.